By Application
Hot products 
-
Mouse Anti-CRYAB Recombinant Antibody (A4345) (CBMAB-A4345-YC)
-
Mouse Anti-4-Hydroxynonenal Recombinant Antibody (V2-502280) (CBMAB-C1055-CN)
-
Mouse Anti-BBS2 Recombinant Antibody (CBYY-0253) (CBMAB-0254-YY)
-
Mouse Anti-ACO2 Recombinant Antibody (V2-179329) (CBMAB-A0627-YC)
-
Rabbit Anti-Acetyl-Histone H3 (Lys36) Recombinant Antibody (V2-623395) (CBMAB-CP0994-LY)
-
Mouse Anti-ELAVL4 Recombinant Antibody (6B9) (CBMAB-1132-YC)
-
Mouse Anti-BPGM Recombinant Antibody (CBYY-1806) (CBMAB-2155-YY)
-
Mouse Anti-CORO1A Recombinant Antibody (4G10) (V2LY-1206-LY806)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7719) (CBMAB-1898CQ)
-
Mouse Anti-FN1 Monoclonal Antibody (D6) (CBMAB-1240CQ)
-
Mouse Anti-ACKR3 Recombinant Antibody (V2-261265) (CBMAB-C1023-LY)
-
Mouse Anti-CAT Recombinant Antibody (724810) (CBMAB-C8431-LY)
-
Mouse Anti-CASP8 Recombinant Antibody (CBYY-C0987) (CBMAB-C2424-YY)
-
Mouse Anti-DLC1 Recombinant Antibody (D1009) (CBMAB-D1009-YC)
-
Mouse Anti-BSN Recombinant Antibody (219E1) (CBMAB-1228-CN)
-
Rabbit Anti-Acetyl-Histone H4 (Lys16) Recombinant Antibody (V2-623415) (CBMAB-CP1021-LY)
-
Rabbit Anti-CAMK2A Recombinant Antibody (BA0032) (CBMAB-0137CQ)
-
Mouse Anti-ADAM12 Recombinant Antibody (V2-179752) (CBMAB-A1114-YC)
-
Mouse Anti-BHMT Recombinant Antibody (CBYY-0547) (CBMAB-0550-YY)
-
Mouse Anti-AOC3 Recombinant Antibody (CBYY-0014) (CBMAB-0014-YY)
Endometrial Cancer
Fig.1 Endometrial cancer
Endometrial cancer is a cancer originating from the endometrium, which is the lining of the womb and uterus. The first sign is most abnormal vaginal bleeding but not associated with menstrual periods. Other symptoms include pain with urination, pelvic pain or sexual intercourse. Endometrial cancer occurs overwhelmingly after menopause. About 40% of cases are related to obesity. Besides it is also associated with diabetes, excessive estrogen exposure and high blood pressure. Hereditary causes contribution to 2–10% of the endometrial cancer cases. The most common type of endometrial cancer is endometrioid carcinoma, which making up more than 80% of cases. The five-year survival rate for endometrial adenocarcinoma following appropriate treatment is around 80%. Prognostic markers, like Serum HE4 have been studied recently.
Loading...
Compare
